Summary
The pharmacokinetics of ornidazole was studied in 6 patients treated by haemodialysis and in 8 subjects with a creatinine clearance between 4 and 99 ml/min × 1.73 m2. Blood and urine collections were performed for 72 h after i.v. and oral administration of 1.0 g ornidazole.
Total body clearance, half-life, volume of distribution and systemic availability were independent of renal function and did not differ from previously reported values in normal volunteers. The haemodialysis clearance of ornidazole was >100% higher than the total body clearance. The renal clearance of ornidazole accounted for less than 7% of the total body clearance. The percentage of the dose of ornidazole recovered in urine as parent compound or as the biologically active metabolites [α-(chloromethyl)-2 hydroxymethyl-5 nitroimidazole-1 ethanol and 3-(2 methyl-5 nitroimidazole-1-yl)1,2 propanediol] decreased linearly with decreasing renal function.
Although the sum of those three compounds recovered in urine accounted for less than 10% of the total dose of ornidazole administered, they yielded therapeutic concentrations (>4 µg/ml) in urine over 24 h after dosing.
Due to the peculiar pharmacokinetic behaviour of ornidazole, i.e. high haemodialysis clearance in the absence of significant renal clearance, no dosage adjustment is necessary while renal function declines, but an increased dose is mandatory while patients are on dialysis.
Similar content being viewed by others
References
Jokipii L, Jokipii AMM (1979) Single-dose metronidazole and tinidazole as therapy for giardiasis: Success rates, side effects, and drug absorption and elimination. J Infect Dis 140: 984–988
Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS (1976) Tinidazole: A review of its antiprotozoal activity and therapeutic efficacy. Drugs 11: 423–440
Kee-Mok C, Hai-Young C, Chin-Thack S (1972) Clinical trials of Ro 7-0207 againstEntamoeba histolytica infections (double blind trials versus metroinidazole). Yonsei Rep Trop Med 3: 123–133
Lean TG, Vengadasalam D (1973) Treatment of vaginal trichomoniasis with a new anti-protozoal compound, α-(cloromethyl)-2-methyl-5-nitro-1-imidazole-ethanol. Br J Vener Dis 49: 69–71
Powell SJ, Elsdon-Dew R (1972) Some new nitroimidazole derivatives — Clinical trials in amoebic liver abscess. Am J Trop Med Hyg 21: 518–520
Ruas A, Ramalho Correia MH, Correia do Valle J, Ataide Ribero J (1973) Ro-7-0207 in amoebic liver abscess. Comparative study of the effects of Ro-7-0207 and metroindazole. Cent Afr J Med 19: 128–132
Delion F, Thebault JJ, Singlas E (1985) Ornidazole: Une ou deux administrations par jour? J Pharm Clin 4: 301–307
Schwartz DE, Jeunet F (1976) Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 22: 19–29
Gibson TP, Atkinson AJ, Matusik E, Nelson LD, Briggs WA (1977) Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 12: 422–429
Horber F, Egger HJ, Weidekamm E, Dubach UC, Frey FJ, Probst PJ, Stoeckel K (1986) Pharmacokinetics of carumonam in patients with renal insufficency. Antimicrob Agents Chemother 29: 116–121
Horber FF, Frey FJ, Descoeudres C, Murray AT, Reubi FC (1986) Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrob Agents Chemother 29: 614–619
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, pp 293
Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074
Gerig JS, Bolton ND, Swabb EA, Scheld WM, Bolton WK (1984) Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int 26: 308–318
Merdjan H, Baumelou A, Diquet B, Chick O, Singlas E (1985) Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis. Br J Clin Pharmacol 19: 211–217
Schwartz DE, Jordan JC, Vetter W, Oesterhelt G (1979) Metabolic studies of ornidazole in the rat, in the dog an in man. Xenobiotica 9: 571–581
Lee CS, Marbury TC, Benet LZ (1980) Clearance calculations in haemodialysis: Application to blood, plasma and dialysate measurements for ethambutol. J Pharmacokin et Biopharm 8: 69–81
Frey FJ, Gambertoglio JG, Frey BM, Benet LZ, Amend WJC (1982) Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol 23: 65–74
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horber, F.F., Maurer, O., Probst, P.J. et al. High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance. Eur J Clin Pharmacol 36, 389–393 (1989). https://doi.org/10.1007/BF00558301
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558301